Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity

Clinical Immunology

Volumn 128, Issue 2, 2008, Pages 155-163

  Guo, Bo ^a   Ma, Zheng wei ^a   Li, Hua ^a   Xu, Gui lian ^a   Zheng, Ping ^a   Zhu, Bo ^a   Wu, Yu Zhang ^a   Zou, Qiang ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

Complement dependent cytotoxicity (CDC); Decay accelerating factor; Immunotherapy; Monoclonal antibody; Tumor

Indexed keywords

CD20 ANTIGEN; DECAY ACCELERATING FACTOR; RITUXIMAB;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAJI CELL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD20; ANTIGENS, CD55; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES; HUMANS;

EID: 46949089844     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.03.507     Document Type: Article

References (30)

1. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5 (2004) 292-302
2. Grillo-Lopez A.J., White C.A., Varns C., Shen D., Wei A., Mcclure A., and Dallaire B.K. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. 26 (1999) 66-73
3. Mclaughlin P., White C.A., Grillo-Lopez A.J., and Maloney D.G. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Huntingt) 12 (1998) 1763-1769
4. Fishelson Z., Donin N., Zell S., Schultz S., and Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol 40 (2003) 109-123
5. Gelderman K.A., Blok V.T., Fleuren G.J., and Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab. Invest. 82 (2002) 483-493
6. Macor P., Tripodo C., Zorzet S., Piovan E., Bossi F., Marzari R., Amadori A., and Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 67 (2007) 10556-10563
7. Durrant L.G., Chapman M.A., Buckley D.J., Spendlove I., Robins R.A., and Armitage N.C. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 52 (2003) 638-642
8. Hiraoka S., Mizuno M., Nasu J., Okazaki H., Makidono C., Okada H., Terada R., Yamamoto K., Fujita T., and Shiratori Y. Enhanced expression of decay-accelerating factor, a complement-regulatory protein, in the specialized intestinal metaplasia of Barrett's esophagus. J. Lab. Clin. Med. 143 (2004) 201-206
9. Ellison B.S., Zanin M.K., and Boackle R.J. Complement susceptibility in glutamine deprived breast cancer cells. Cell Div. 2 (2007) 20
10. Terui Y., Sakurai T., Mishima Y., Mishima Y., Sugimura N., Sasaoka C., Kojima K., Yokoyama M., Mizunuma N., Takahashi S., Ito Y., and Hatake K. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci. 97 (2006) 72-79
11. Zell S., Geis N., Rutz R., Schultz S., Giese T., and Kirschfink M. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin. Exp. Immunol. 150 (2007) 576-584
12. Zou Q., Xie P.R., and Zheng P. Preparation and identification of mAbs against human decay-accelerating factor. Immunol. J. 15 (1999) 122-124
13. Gietz R.D., Schiestl R.H., Willems A.R., and Woods R.A. Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast 11 (1995) 355-360
14. Prezzi C., Nuzzo M., Meola A., Delmastro P., Galfre G., Cortese R., Nicosia A., and Monaci P. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. J. Immunol. 156 (1996) 4504-4513
15. Felici F., Castagnoli L., Musacchio A., Jappelli R., and Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J. Mol. Biol. 222 (1991) 301-310
16. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., Tedesco F., Rambaldi A., and Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 (2000) 3900-3908
17. Lublin D.M., and Atkinson J.P. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7 (1989) 35-58
18. Cochran J.R., Kim Y.S., Olsen M.J., Bhandari R., and Wittrup K.D. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J. Immunol. Methods 287 (2004) 147-158
19. Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P., Delwail V., Deconinck E., Haioun C., Foussard C., Sebban C., Stamatoullas A., Milpied N., Boue F., Taillan B., Lederlin P., Najman A., Thieblemont C., Montestruc F., Mathieu-Boue A., Benzohra A., and Solal-Celigny P. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
20. Mclaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D., and Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 (1998) 2825-2833
21. Bellosillo B., Villamor N., Lopez-Guillermo A., Marce S., Esteve J., Campo E., Colomer D., and Montserrat E. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98 (2001) 2771-2777
22. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T., Rambaldi A., and Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 (2001) 3383-3389
23. Jurianz K., Ziegler S., Garcia-Schuler H., Kraus S., Bohana-Kashtan O., Fishelson Z., and Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol. 36 (1999) 929-939
24. Coyne K.E., Hall S.E., Thompson S., Arce M.A., Kinoshita T., Fujita T., Anstee D.J., Rosse W., and Lublin D.M. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149 (1992) 2906-2913
25. Hara T., Matsumoto M., Fukumori Y., Miyagawa S., Hatanaka M., Kinoshita T., Seya T., and Akedo H. A monoclonal antibody against human decay-accelerating factor (DAF, CD55), D17, which lacks reactivity with semen-DAF. Immunol. Lett. 37 (1993) 145-152
26. Medof M.E., Walter E.I., Roberts W.L., Haas R., and Rosenberry T.L. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 25 (1986) 6740-6747
27. Ratnoff W.D., Knez J.J., Prince G.M., Okada H., Lachmann P.J., and Medof M.E. Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin. Exp. Immunol. 87 (1992) 415-421
28. Brodbeck W.G., Liu D., Sperry J., Mold C., and Medof M.E. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J. Immunol. 156 (1996) 2528-2533
29. Gevorkian G., Petrushina I., Manoutcharian K., Ghochikyan A., Acero G., Vasilevko V., Cribbs D.H., and Agadjanyan M.G. Mimotopes of conformational epitopes in fibrillar beta-amyloid. J. Neuroimmunol. 156 (2004) 10-20
30. Wu S.C., and Lin C.W. Neutralizing peptide ligands selected from phage-displayed libraries mimic the conformational epitope on domain III of the Japanese encephalitis virus envelope protein. Virus Res. 76 (2001) 59-69